ioxaglate

ioxaglate

 [i″ok-sag´lāt]
a low-osmolality radiopaque medium, used as the meglumine or sodium salt.

i·ox·ag·late

(ī'oks-ag'lāt),
A diagnostic radiopaque medium, usually a combination of ioxaglate meglumine and ioxaglate sodium; used in angiography, aortography, arteriography, venography, and urography.

ioxaglate

/iox·ag·late/ (i″ok-sag´lāt) a low-osmolality radiopaque medium, used as the meglumine or sodium salt.
Mentioned in ?
References in periodicals archive ?
In another study, Ribeiro et al (21) investigated NO production in rat renal artery smooth muscle cells primary culture (rVSMC) exposed to contrast medium and found that non ionic iobitridol, low-osmolar ioxaglate and high-osmolar ioxitalamate caused decreases in NO levels as compared to control.
In vitro, Arranz-Pena and coworkers have compared the interference by 13 different iodinated contrast agents on the Paragon by adding the different agents to control serum, and found that most agents caused a peak in the [alpha]2 fraction, but some agents (sodiummeglumine ioxaglate, ioversol, and iomeprol) caused interference in the [beta]-fraction (4).
They were randomized to receive either Ioxaglate (74 patients) or Iodixanol (71 patients) during their procedures.
From these data we conclude there is absolutely no indication that iodixanol is less harmful for kidney function than ioxaglate or iohexol," Dr.
Within 1 year of coronary angiography or PCI, 70 of 5,728 patients given iohexol (Omnipaque) and 291 of 24,577 patients given ioxaglate (Hexabrix) returned to a hospital with a renal failure diagnosis.
2]-globulin fraction for iohexol, at the anodal site of the [beta]-globulin fraction for sodium-meglumine ioxaglate, and in the middle of the [beta]-globulin fraction for ioversol.
2]-Globulin lopamiro Iopamidol 242 (cathodal site) Omnitrast Iohexol 242 Omnipaque Iohexol 242 Ultravist Iopromide 242 R-Globulin (anodal site) Hexabrix Sodium-meglumine 243 ioxaglate R-Globulin (middle site) Optiray Ioversol 244 Iomeron Iomeprol 244
In it, patients with high-risk cardiac conditions, such as evolving acute MI, unstable angina, or post-MI ischemia, were randomly assigned to receive either the nonionic isosmolar contrast agent Visipaque(R) (iodixanol), or the ionic low osmolar contrast agent ioxaglate, during their coronary artery balloon angioplasty and/or stent placement procedures.